Caroline K Kramer1,2,3, Sara Campbell1, Ravi Retnakaran4,5,6. 1. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, 60 Murray Street, Suite L5-025, Mailbox-21, Toronto, ON, M5T 3L9, Canada. 2. Division of Endocrinology, University of Toronto, Toronto, ON, Canada. 3. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. 4. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, 60 Murray Street, Suite L5-025, Mailbox-21, Toronto, ON, M5T 3L9, Canada. Ravi.Retnakaran@sinaihealthsystem.ca. 5. Division of Endocrinology, University of Toronto, Toronto, ON, Canada. Ravi.Retnakaran@sinaihealthsystem.ca. 6. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. Ravi.Retnakaran@sinaihealthsystem.ca.
Abstract
AIMS/HYPOTHESIS: Women who develop gestational diabetes mellitus (GDM) have an elevated lifetime risk of type 2 diabetes mellitus. Recently, a series of studies has suggested that women with GDM also have an increased risk of cardiovascular disease (CVD). However, it is unclear if this risk is dependent upon the intercurrent development of type 2 diabetes. Thus, we conducted a systematic review and meta-analysis to evaluate the impact of GDM on future risk of incident CVD and to ascertain the role of type 2 diabetes in this regard. METHODS: We systematically searched the PubMed and EMBASE databases for observational studies that evaluated the association of GDM with subsequent CVD, with publication between 1 January 1950 and 30 August 2018. Two independent reviewers extracted data and the analysis was performed in accordance with Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. RRs were calculated using a random-effects model to assess the predictive value of GDM for future cardiovascular events. To evaluate whether incident type 2 diabetes in the GDM population influenced the association with CVD, we used meta-regression models followed by sensitivity analyses restricted to women who did not develop type 2 diabetes during follow-up. RESULTS: A pooled analysis of nine studies yielded data from 5,390,591 women (101,424 cardiovascular events). Compared with those who did not have GDM, women with GDM had a twofold higher risk of future cardiovascular events (RR 1.98 [95% CI 1.57, 2.50]). Meta-regression analysis showed that the rates of incident type 2 diabetes across the studies did not affect this risk (p = 0.34). Moreover, when restricted to women who did not develop type 2 diabetes, GDM remained associated with a 56% higher risk of future cardiovascular events (RR 1.56 [95% CI 1.04, 2.32]). GDM conferred a 2.3-fold increased risk of cardiovascular events in the first decade postpartum (RR 2.31 [95% CI 1.57, 3.39]). CONCLUSIONS/ INTERPRETATION: The diagnosis of GDM identifies young women who have a twofold higher risk of cardiovascular events postpartum compared with their peers. This risk is not dependent upon intercurrent type 2 diabetes and is apparent within the first decade after pregnancy. Thus, even without progressing to type 2 diabetes, women with GDM comprise an at-risk population for CVD and hence a potential opportunity for early risk factor surveillance and risk modification.
AIMS/HYPOTHESIS: Women who develop gestational diabetes mellitus (GDM) have an elevated lifetime risk of type 2 diabetes mellitus. Recently, a series of studies has suggested that women with GDM also have an increased risk of cardiovascular disease (CVD). However, it is unclear if this risk is dependent upon the intercurrent development of type 2 diabetes. Thus, we conducted a systematic review and meta-analysis to evaluate the impact of GDM on future risk of incident CVD and to ascertain the role of type 2 diabetes in this regard. METHODS: We systematically searched the PubMed and EMBASE databases for observational studies that evaluated the association of GDM with subsequent CVD, with publication between 1 January 1950 and 30 August 2018. Two independent reviewers extracted data and the analysis was performed in accordance with Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. RRs were calculated using a random-effects model to assess the predictive value of GDM for future cardiovascular events. To evaluate whether incident type 2 diabetes in the GDM population influenced the association with CVD, we used meta-regression models followed by sensitivity analyses restricted to women who did not develop type 2 diabetes during follow-up. RESULTS: A pooled analysis of nine studies yielded data from 5,390,591 women (101,424 cardiovascular events). Compared with those who did not have GDM, women with GDM had a twofold higher risk of future cardiovascular events (RR 1.98 [95% CI 1.57, 2.50]). Meta-regression analysis showed that the rates of incident type 2 diabetes across the studies did not affect this risk (p = 0.34). Moreover, when restricted to women who did not develop type 2 diabetes, GDM remained associated with a 56% higher risk of future cardiovascular events (RR 1.56 [95% CI 1.04, 2.32]). GDM conferred a 2.3-fold increased risk of cardiovascular events in the first decade postpartum (RR 2.31 [95% CI 1.57, 3.39]). CONCLUSIONS/ INTERPRETATION: The diagnosis of GDM identifies young women who have a twofold higher risk of cardiovascular events postpartum compared with their peers. This risk is not dependent upon intercurrent type 2 diabetes and is apparent within the first decade after pregnancy. Thus, even without progressing to type 2 diabetes, women with GDM comprise an at-risk population for CVD and hence a potential opportunity for early risk factor surveillance and risk modification.
Entities:
Keywords:
Cardiovascular disease; Gestational diabetes; Meta-analysis; Risk factors; Systematic review; Type 2 diabetes; Women’s health
Authors: Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner Journal: Circulation Date: 2014-12-17 Impact factor: 29.690
Authors: Ravi Retnakaran; Ying Qi; Philip W Connelly; Mathew Sermer; Anthony J Hanley; Bernard Zinman Journal: J Clin Endocrinol Metab Date: 2010-07-14 Impact factor: 5.958
Authors: Ravi Retnakaran; Ying Qi; Philip W Connelly; Mathew Sermer; Bernard Zinman; Anthony J G Hanley Journal: J Clin Endocrinol Metab Date: 2009-11-19 Impact factor: 5.958
Authors: Derrick C V Shostrom; Yangbo Sun; Jacob J Oleson; Linda G Snetselaar; Wei Bao Journal: Front Endocrinol (Lausanne) Date: 2017-06-26 Impact factor: 5.555
Authors: Barbara Daly; Konstantinos A Toulis; Neil Thomas; Krishna Gokhale; James Martin; Jonathan Webber; Deepi Keerthy; Kate Jolly; Ponnusamy Saravanan; Krishnarajah Nirantharakumar Journal: PLoS Med Date: 2018-01-16 Impact factor: 11.069
Authors: Lois McCloskey; Judith Bernstein; Linda Goler-Blount; Ann Greiner; Anna Norton; Emily Jones; Chloe E Bird Journal: Womens Health Issues Date: 2021-03-07
Authors: Maleesa M Pathirana; Zohra S Lassi; Anna Ali; Margaret A Arstall; Claire T Roberts; Prabha H Andraweera Journal: Endocrine Date: 2020-09-15 Impact factor: 3.633
Authors: Emma V Preston; Sheryl L Rifas-Shiman; Marie-France Hivert; Ami R Zota; Sharon K Sagiv; Antonia M Calafat; Emily Oken; Tamarra James-Todd Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Katrien Benhalima; Paul Van Crombrugge; Carolien Moyson; Johan Verhaeghe; Sofie Vandeginste; Hilde Verlaenen; Chris Vercammen; Toon Maes; Els Dufraimont; Christophe De Block; Yves Jacquemyn; Farah Mekahli; Katrien De Clippel; Annick Van Den Bruel; Anne Loccufier; Annouschka Laenen; Caro Minschart; Roland Devlieger; Chantal Mathieu Journal: Acta Diabetol Date: 2020-01-08 Impact factor: 4.280
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602
Authors: Amanda M Perak; Nicola Lancki; Alan Kuang; Darwin R Labarthe; Norrina B Allen; Svati H Shah; Lynn P Lowe; William A Grobman; Denise M Scholtens; Donald M Lloyd-Jones; William L Lowe Journal: Am J Obstet Gynecol Date: 2020-08-05 Impact factor: 8.661